Institute for Integrative Gastroenterology
@gutscience.org
Advancing gut health through microbiome research, clinical insight, and education. Translating science into better medicine. gutscience.org
Diet can be an IBS treatment. In post-hoc tests, only low-FODMAP plus advice differed from the drug arm.
In 294 adults, 4-week ≥50-point IBS-SSS response: 76% low-FODMAP plus advice, 71% experimental low-carb/high-fat, 58% one symptom-targeted drug.
pubmed.ncbi.nlm.nih.gov/38643782/
In 294 adults, 4-week ≥50-point IBS-SSS response: 76% low-FODMAP plus advice, 71% experimental low-carb/high-fat, 58% one symptom-targeted drug.
pubmed.ncbi.nlm.nih.gov/38643782/
A low FODMAP diet plus traditional dietary advice versus a low-carbohydrate diet versus pharmacological treatment in irritable bowel syndrome (CARIBS): a single-centre, single-blind, randomised controlled trial - PubMed
The Healthcare Board Region Västra Götaland, the Swedish Research Council, the Swedish Research Council for Health, Working Life and Welfare, AFA Insurance, grants from the Swedish state, the Wilhelm and Martina Lundgren Science Foundation, Skandia, the Dietary Science Foundation, and the Nanna Swar …
pubmed.ncbi.nlm.nih.gov
August 13, 2026 at 10:09 PM
Diet can be an IBS treatment. In post-hoc tests, only low-FODMAP plus advice differed from the drug arm.
In 294 adults, 4-week ≥50-point IBS-SSS response: 76% low-FODMAP plus advice, 71% experimental low-carb/high-fat, 58% one symptom-targeted drug.
pubmed.ncbi.nlm.nih.gov/38643782/
In 294 adults, 4-week ≥50-point IBS-SSS response: 76% low-FODMAP plus advice, 71% experimental low-carb/high-fat, 58% one symptom-targeted drug.
pubmed.ncbi.nlm.nih.gov/38643782/
A regulated microbiota treatment can help prevent recurrent C. difficile infection.
In 182 adults, recurrence through 8 weeks was 12.4% with SER-109 and 39.8% with placebo. Now FDA-approved as Vowst, it is used after antibiotics, not instead of them.
pubmed.ncbi.nlm.nih.gov/35045228/
In 182 adults, recurrence through 8 weeks was 12.4% with SER-109 and 39.8% with placebo. Now FDA-approved as Vowst, it is used after antibiotics, not instead of them.
pubmed.ncbi.nlm.nih.gov/35045228/
August 12, 2026 at 1:39 AM
A regulated microbiota treatment can help prevent recurrent C. difficile infection.
In 182 adults, recurrence through 8 weeks was 12.4% with SER-109 and 39.8% with placebo. Now FDA-approved as Vowst, it is used after antibiotics, not instead of them.
pubmed.ncbi.nlm.nih.gov/35045228/
In 182 adults, recurrence through 8 weeks was 12.4% with SER-109 and 39.8% with placebo. Now FDA-approved as Vowst, it is used after antibiotics, not instead of them.
pubmed.ncbi.nlm.nih.gov/35045228/
A randomized trial tested pasteurized A. muciniphila in 143 adults with metabolic syndrome. Whole-body insulin sensitivity at 4 months, the primary endpoint, did not improve. Favorable findings appeared in exploratory subgroups and need confirmation.
doi.org/10.1080/1949...
doi.org/10.1080/1949...
Effect of pasteurized Akkermansia muciniphila MucT on insulin sensitivity, body composition, and GLP-1 production in subjects with metabolic syndrome: impact of low baseline gut Akkermansia levels
Pasteurized Akkermansia muciniphila MucT was found to improve barrier function in preclinical models and a proof-of-concept study in obese and prediabetic adults. Here, we describe the results of a...
doi.org
August 9, 2026 at 4:14 PM
A randomized trial tested pasteurized A. muciniphila in 143 adults with metabolic syndrome. Whole-body insulin sensitivity at 4 months, the primary endpoint, did not improve. Favorable findings appeared in exploratory subgroups and need confirmation.
doi.org/10.1080/1949...
doi.org/10.1080/1949...
The Institute for Integrative Gastroenterology works at the intersection of microbiome science, clinical research, and medical innovation.
Here we will discuss new papers and unresolved questions in gastroenterology and the microbiome.
Here we will discuss new papers and unresolved questions in gastroenterology and the microbiome.
August 8, 2026 at 2:42 PM
The Institute for Integrative Gastroenterology works at the intersection of microbiome science, clinical research, and medical innovation.
Here we will discuss new papers and unresolved questions in gastroenterology and the microbiome.
Here we will discuss new papers and unresolved questions in gastroenterology and the microbiome.